ALK and neoplasm: The signal-seeking MyPathway trial (NCT02091141)28 completed in 2023 and additional studies to investigate ALK TKIs in adult and pediatric patients in a tumor-agnostic setting are currently ongoing or completed (eg, TAPISTRY platform study [NCT04589845]29; iMATRIX study [NCT04774718]30).